Duesseldorf, 9 September 9, 2021 – At its most recent meeting, the Supervisory Board of Gerresheimer prematurely extended the contract of chief financial officer Dr Bernd Metzner (50) by a further five years until May 2027. The move is a strong sign of continuity and reliability for the management board of Gerresheimer. Together, the three management board members Dietmar Siemssen, Dr Bernd Metzner and Dr Lukas Burkhardt will continue to drive forward the formula G strategy, which calls for Gerresheimer’s transformation into a growth company as an innovation leader and solution provider.
Dr Metzner has already been chief financial officer of Gerresheimer since May 2019. His contract runs until May 2027, meaning that all three Management Board members have now extended their contracts by five years. “We have initiated a transformation together in recent years, marking the start of an exciting journey toward sustainable, profitable growth. I look forward to continuing to successfully shape the future of our Gerresheimer together with my management board colleagues and the entire Gerresheimer team. At the same time, I would like to thank our supervisory board for its trust,” says Dr Metzner.
“It is clear to us that Dr. Bernd Metzner is the ideal CFO for our company. With his longstanding expertise, he will continue to make a significant contribution to achieving our ambitious growth targets sustainably,” says Dietmar Siemssen, CEO of Gerresheimer. “We are all looking forward to continuing to work together.”
Gerresheimer is the global partner for pharma, biotech, healthcare and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging and drug delivery devices. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia with around 10,000 employees and annual sales of more than €1.4 billion.
